Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma

被引:31
作者
Nakajima, T [1 ]
Moriguchi, M
Mitsumoto, Y
Sekoguchi, S
Nishikawa, T
Takashima, H
Watanabe, T
Katagishi, T
Kimura, H
Okanoue, T
Kagawa, K
机构
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan
[2] Fukuchiyama City Hosp, Dept Internal Med, Fukuchiyama, Japan
关键词
centrosome; p53; genetic instability; hepatocellular carcinoma;
D O I
10.1038/modpathol.3800115
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Centrosome duplication is controlled in a cell cycle-specific manner and occurs once every cell cycle, thereby ensuring the balanced segregation of chromosomes during the mitotic phase. Numerical or structural abnormalities can arise in the centrosomes of malignant cells. Under defective cell cycle checkpoint systems, cancer cells with abnormal centrosomes can survive and re-enter the cell cycle, promoting unbalanced chromosome segregation and genetic instability. We investigated the centrosome aberrations in 33 patients diagnosed with hepatocellular carcinoma (HCC), using fluorescent pericentrin immunostaining. We also studied the p53 mutation, proliferative activity, and DNA ploidy in these cases. In normal hepatocytes, one centrosome was identified per cell as a round dot, usually in the vicinity of the nuclear membrane. However, in cancer cells from HCC tissue, several patterns of centrosome abnormalities occurred, including supernumerary centrosomes; and centrosomes with an abnormal shape and size. Although the frequency of abnormal centrosomes in each tissue was relatively low compared with previous reports in other cancers, nevertheless, centrosome aberration was found in 30 out of 33 HCC tissues. The percentage of tumor cells with abnormal centrosomes was significantly higher in the nondiploid tumors (15.8+/-15.9parts per thousand.) than in the diploid tumors (5.4+5.1parts per thousand) (P<0.05), and tended to be higher in the tumors with p53 mutation (11.6 +/- 13.1 parts per thousand.) than in those with wild-type p53 (5.6 +/- 6.8 parts per thousand). Furthermore, 82% of nondiploid tumors exhibited p53 mutation, whereas only 41% of diploid tumors showed p53 mutation. The percentage of tumor cells with centrosome abnormalities were not related to tumor stage, size or proliferative activity. Therefore, our results indicate that hepatic cancer cells, under centrosome aberration and a defective checkpoint system possibly caused by p53 mutation, have the potential for genetic instability and aggressive behavior. This potential effect occurs irrespective of the tumor size or stage.
引用
收藏
页码:722 / 727
页数:6
相关论文
共 27 条
[1]   Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells [J].
Borel, F ;
Lohez, OD ;
Lacroix, FB ;
Margolis, RL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :9819-9824
[2]   CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells [J].
Chen, ZH ;
Indjeian, VB ;
McManus, M ;
Wang, LY ;
Dynlacht, BD .
DEVELOPMENTAL CELL, 2002, 3 (03) :339-350
[3]   p53 displacement from centrosomes and p53-mediated G1 arrest following transient inhibition of the mitotic spindle [J].
Ciciarello, M ;
Mangiacasale, R ;
Casenghi, M ;
Limongi, MZ ;
D'Angelo, M ;
Soddu, S ;
Lavia, P ;
Cundari, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (22) :19205-19213
[4]   Abnormal centrosome amplification in the absence of p53 [J].
Fukasawa, K ;
Choi, T ;
Kuriyama, R ;
Rulong, S ;
VandeVoude, GF .
SCIENCE, 1996, 271 (5256) :1744-1747
[5]   Genomic instability and apoptosis are frequent in p53 deficient young mice [J].
Fukasawa, K ;
Wiener, F ;
VandeWoude, GF ;
Mai, SB .
ONCOGENE, 1997, 15 (11) :1295-1302
[6]  
Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331
[7]   Alteration of numerical chromosomal aberrations during progression of colorectal tumors revealed by a combined fluorescence in situ hybridization and DNA ploidy analysis of intratumoral heterogeneity [J].
Katsura, K ;
Sugihara, H ;
Nakai, S ;
Fujita, S .
CANCER GENETICS AND CYTOGENETICS, 1996, 90 (02) :146-153
[8]  
Kimura H, 1996, CANCER, V77, P271, DOI 10.1002/(SICI)1097-0142(19960115)77:2<271::AID-CNCR8>3.0.CO
[9]  
2-P
[10]   EVALUATION OF PROLIFERATIVE ACTIVITY IN HEPATOCELLULAR-CARCINOMA BY KI-67 IMMUNOSTAINING OF PARAFFIN-EMBEDDED TISSUES AFTER ANTIGEN RETRIEVAL [J].
KIMURA, H ;
KAGAWA, K ;
DEGUCHI, T ;
NAKAJIMA, T ;
OHKAWARA, T ;
KAKUSUI, M ;
OKANOUE, T ;
KASHIMA, K .
INTERNATIONAL HEPATOLOGY COMMUNICATIONS, 1994, 2 (02) :99-104